Journal of Personalized Medicine (Jul 2022)

Analysis of Mortality in Intracerebral Hemorrhage Patients with Hyperacute Ischemic Stroke Treated Using Thrombolytic Therapy: A Nationwide Population-based Cohort Study in South Korea

  • Hyun-Young Choi,
  • Yongil Cho,
  • Wonhee Kim,
  • Yang-Ki Minn,
  • Gu-Hyun Kang,
  • Yong-Soo Jang,
  • Yoonje Lee,
  • Jae-Guk Kim,
  • Jihoon Kim,
  • Youngsuk Cho,
  • Hyungoo Shin,
  • Shinje Moon,
  • Chiwon Ahn,
  • Juncheol Lee,
  • Dong-Geum Shin,
  • Jae-Keun Park

DOI
https://doi.org/10.3390/jpm12081260
Journal volume & issue
Vol. 12, no. 8
p. 1260

Abstract

Read online

This study investigated the impact of intracerebral hemorrhage (ICH) on the cumulative mortality of patients with hyperacute ischemic stroke. This population-based retrospective cohort study used claims data from the National Health Insurance Service customized database of South Korea. The recruitment period was 2005–2018. The study population included patients with hyperacute ischemic stroke who had received intravenous thrombolysis. The primary endpoint was 12-month cumulative mortality, which was analyzed in both the ICH and no-ICH groups. Of the 50,550 patients included, 2567 (5.1%) and 47,983 (94.9%) belonged to the ICH and no-ICH groups, respectively. In the univariable analysis for 12-month mortality, ICH patients were substantially more prevalent among dead patients than among patients who survived (11.6% versus 3.6%; p p < 0.001). In the multivariable analysis, the risk of 12-month cumulative mortality was 2.97 times higher in the ICH group than in the no-ICH group (95% confidence interval, 2.79–3.16). The risk of 12-month cumulative mortality in hyperacute ischemic stroke can increase approximately threefold after the occurrence of spontaneous ICH following intravenous thrombolysis.

Keywords